Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
Merck Sharp & Dohme LLC
Nurix Therapeutics, Inc.
AbbVie
ModeX Therapeutics, An OPKO Health Company
Newave Pharmaceutical Inc
Schrödinger, Inc.
AbbVie
BeOne Medicines
Carna Biosciences, Inc.
Dana-Farber Cancer Institute
University of Ulm
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Accutar Biotechnology Inc
Northwell Health
Centre Hospitalier Universitaire, Amiens
Stanford University
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
BeiGene
Nurix Therapeutics, Inc.
Institute of Hematology & Blood Diseases Hospital, China
University College, London
Kosin University Gospel Hospital